NIH RAC should encourage serious disease studies over genetic enhancement protocols -- NORD's Langan.
NIH RAC SHOULD PROMOTE SERIOUS GENETIC DISEASE PROTOCOLS OVER ENHANCEMENT studies, National Organization for Rare Disorders VP-Public Policy Michael Langan, urged at the first NIH gene therapy policy conference on genetic enhancement. The National Institutes of Health Recombinant DNA Advisory Committee should consider "a way to encourage more scientists to research these truly serious and life-threatening diseases, and to discourage enhancement," Langan said at the Sept. 11 meeting in Bethesda, Md.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth